Seelos therapeutics provides update on top-line results from its amyotrophic lateral sclerosis (als) study with sls-005 (iv trehalose)

New york, march 19, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the phase 2/3 healey als platform trial. this study was performed in collaboration with the sean m.
SEEL Ratings Summary
SEEL Quant Ranking